Birgit C. Schultes net worth and biography

Birgit Schultes Biography and Net Worth

Birgit Schultes oversees all platform and pipeline research activities across in vivo and ex vivo (engineered cell therapy) areas as Intellia’s chief scientific officer. With over two decades’ experience in the biotechnology and pharmaceutical industry, Birgit brings deep immunology and cell therapy expertise to Intellia. She manages a multidisciplinary team focused on ex vivo applications of CRISPR/Cas9 to generate novel cell therapies for oncology and autoimmune indications. Prior to joining Intellia, Birgit served as senior director, In Vivo and Exploratory Immunology, at Unum Therapeutics (now Cogent Biosciences, Inc.), where she was responsible for its In Vivo team and leading its exploratory immunology efforts. Earlier in her career, Birgit held a variety of translational research roles in biology and immunology at Momenta Pharmaceuticals, United Therapeutics and AltaRex Corp. Additionally, Birgit co-founded and served as scientific advisor at Advanced Immune Therapeutics, a company working to develop novel cancer therapeutics.

Birgit received her M.S. in Biology and Ph.D. in Immunology from the University of Bonn, Germany, and a degree in Advanced Management Development from Boston University.

What is Birgit C. Schultes' net worth?: The estimated net worth of Birgit C. Schultes is at least $1.02 million as of October 1st, 2025. Schultes owns 105,184 shares of Intellia Therapeutics stock worth more than $1,024,492 as of December 5th. This net worth evaluation does not reflect any other investments that Schultes may own. Learn More about Birgit C. Schultes' net worth.
How do I contact Birgit C. Schultes?: The corporate mailing address for Schultes and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on Birgit C. Schultes' contact information.
Has Birgit C. Schultes been buying or selling shares of Intellia Therapeutics?: During the past quarter, Birgit C. Schultes has sold $538.78 in shares of Intellia Therapeutics stock. Most recently, Birgit C. Schultes sold 31 shares of the business's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a transaction totalling $538.78. Following the completion of the sale, the executive vice president now directly owns 105,184 shares of the company's stock, valued at $1,828,097.92. Learn More on Birgit C. Schultes' trading history.
Who are Intellia Therapeutics' active insiders?: Intellia Therapeutics' insider roster includes James Basta (EVP, General Counsel and Corporate Secretary), William Chase (Director), Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Michael Dube (CAO), Jean-Francois Formela (Director), Glenn Goddard (CFO), Jesse Goodman (Director), J III (EVP), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), Birgit Schultes (EVP), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?: In the last year, Intellia Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,003,000.00. In the last year, insiders at the sold shares 11 times. They sold a total of 43,701 shares worth more than $541,697.15. The most recent insider tranaction occured on October, 1st when EVP Birgit C Schultes sold 31 shares worth more than $538.78. Insiders at Intellia Therapeutics own 3.1% of the company. Learn More about insider trades at Intellia Therapeutics.
Information on this page was last updated on 10/1/2025.

Birgit C. Schultes Insider Trading History at Intellia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/1/2025	Sell	31	$17.38	$538.78	105,184

Birgit C. Schultes Buying and Selling Activity at Intellia Therapeutics

Intellia Therapeutics Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $9.74

$8.85

$9.92

50 Day Range

MA: $15.47

$8.04

$27.98

2 Week Range

Now: $9.74

$5.90

$28.25

Volume

5,893,115 shs

Average Volume

6,755,643 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13